Literature DB >> 6693055

Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients.

J G Aalders, V Abeler, P Kolstad.   

Abstract

Three hundred and seventy-nine patients with recurrent endometrial cancer were seen in the Norwegian Radium Hospital from 1960 to 1976. Local recurrence was found in 190 patients (50%), distant metastases in 108 patients (28%), and in 81 patients (21%) local recurrence and distant metastases were found simultaneously. Thirty-two percent of all patients had no symptoms at the time of diagnosis of the recurrence. The median time interval between primary treatment and detection of recurrence was 14 months for patients with local recurrence and 19 months for those with distant metastases. Thirty-four percent of all recurrences was detected within 1 year and 76% within three years of primary treatment. In 10% recurrence was diagnosed more than 5 years after primary treatment. Twenty-two of the 190 patients (12%) with local recurrence, 5 of the 108 patients (5%) with distant metastases, and 2 of the 81 patients (2%) with local recurrence together with distant metastases survived and were without evidence of disease at the end of the observation period (3-19 years). Radiotherapy alone or in combination with surgery was given in 24 of the 29 "cured" patients; 16 of them received progestagens in addition. Three of the survivors were treated with progestagens alone. The median survival time for patients with lung metastases only, who were treated with progestagens, was considerably longer when compared to those without treatment (9 vs 2 months). The need for nonhormonal cytotoxic chemotherapy in the treatment of recurrent endometrial carcinoma is stressed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693055     DOI: 10.1016/0090-8258(84)90063-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Solitary brain metastases from uterus carcinoma: report of three cases.

Authors:  M Salvati; E Caroli; E Ramundo Orlando; A Nardone; A Frati; G Innocenzi; F Giangaspero
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

2.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer.

Authors:  O O Agboola; E Grunfeld; D Coyle; G A Perry
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

3.  Which is worse: uterine papillary serous carcinomas or carcinosarcomas?

Authors:  Taejong Song; Chel Hun Choi; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

4.  Hematogenous metastases in patients with Stage I or II endometrial carcinoma.

Authors:  Paweł Blecharz; Krzysztof Urbański; Anna Mucha-Małecka; Krzysztof Małecki; Marian Reinfuss; Jerzy Jakubowicz; Piotr Skotnicki
Journal:  Strahlenther Onkol       Date:  2011-11-17       Impact factor: 3.621

Review 5.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

6.  Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer.

Authors:  Ya-Ting Hsu; Fei Gu; Yi-Wen Huang; Joseph Liu; Jianhua Ruan; Rui-Lan Huang; Chiou-Miin Wang; Chun-Liang Chen; Rohit R Jadhav; Hung-Cheng Lai; David G Mutch; Paul J Goodfellow; Ian M Thompson; Nameer B Kirma; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

Review 7.  Endometrial carcinoma with cerebellar metastasis: a case report and review of the literature.

Authors:  Sanjeev Sewak; Franco M Muggia; David Zagzag
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

8.  Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.

Authors:  Sang-Young Ryu; Kidong Kim; Younha Kim; Sang-Il Park; Beob-Jong Kim; Moon-Hong Kim; Seok-Cheol Choi; Eui-Don Lee; Kyung-Hee Lee; Byung Il Kim
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

9.  The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Chikako Fukushima; Tomoko Haruma; Chiaki Hayashi; Tomoyuki Kusumoto; Noriko Seki; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

10.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.